Orchid Pharma Limited (ORCHPHARMA.NS)
INR 1794.0
(0.9%)
INR 1794.0
(0.9%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 1.21 Billion | 185.82 Million | 924.74 Million | 235.86 Million | 808.03 Million | 120.24 Million |
| Net Income | 921.66 Million | 463.18 Million | -19.51 Million | -1.16 Billion | -1.31 Billion | 694.07 Million |
| Depreciation & Amortization | 332.37 Million | 547.86 Million | 870.24 Million | 1.08 Billion | 1.25 Billion | 1.29 Billion |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | -78.37 Million | -790.62 Million | 595.65 Million | -369.59 Million | 618.85 Million | -1.1 Billion |
| Other non-cash items | 315.37 Million | -34.6 Million | -521.64 Million | 681.59 Million | 240.66 Million | -768.84 Million |
| Investing Cash Flow | -3.24 Billion | -314.58 Million | 1.12 Billion | 672.05 Million | 1.67 Billion | 454.73 Million |
| Investments in PPE | -648.14 Million | -849.13 Million | -144.03 Million | -6.04 Million | -42.42 Million | -66.26 Million |
| Acquisitions | - | 576.1 Million | 1.13 Billion | 2.86 Million | - | -372.29 Million |
| Investment purchases | -2.59 Billion | -53.07 Million | -128.44 Million | -130.78 Million | - | -17 Thousand |
| Sales/Maturities of investments | - | -525.47 Million | 128.44 Million | 799.31 Million | 1.47 Billion | 372.31 Million |
| Other Investing Activities | -2.47 Billion | 536.99 Million | 134.31 Million | 6.7 Million | 241.75 Million | 520.99 Million |
| Financing Cash Flow | 1.83 Billion | 311.66 Million | -2.16 Billion | -1.64 Billion | -2.5 Billion | -2.99 Million |
| Debt repayment | -2.08 Billion | -1.09 Billion | -2.04 Billion | -1.25 Billion | -10.44 Billion | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 3.91 Billion | - | - | - | 400 Million | - |
| Other Financing Activities | 3.75 Billion | 1.4 Billion | -120.12 Million | -399.08 Million | 7.53 Billion | -2.99 Million |
| Accounts receivables | 196.46 Million | -416.53 Million | -229.19 Million | -820.24 Million | 440.11 Million | -91.49 Million |
| Accounts payables | 548.51 Million | 139.14 Million | 473.62 Million | 179.3 Million | 76.91 Million | -576.76 Million |
| Inventory | -354.88 Million | -560.81 Million | 25.36 Million | -334.98 Million | 140.62 Million | 239.66 Million |
| Other working capital | -468.47 Million | 47.59 Million | 325.85 Million | 606.33 Million | -38.8 Million | -675.82 Million |
| Cash at beginning of period | 266.11 Million | 43.06 Million | 156.93 Million | 898.91 Million | 923.1 Million | 351.13 Million |
| Cash at end of period | 2.66 Billion | 225.97 Million | 43.06 Million | 156.93 Million | 898.91 Million | 923.1 Million |
| Capital Expenditure | -648.14 Million | -849.13 Million | -144.03 Million | -6.04 Million | -42.42 Million | -66.26 Million |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | 2.39 Billion | 182.9 Million | -113.87 Million | -741.97 Million | -24.19 Million | 571.97 Million |
| Free Cash Flow | 568.24 Million | -663.3 Million | 780.71 Million | 229.82 Million | 765.6 Million | 53.97 Million |
| Breakdown | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 | 2023 Q1 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 293.5 Million | 335.26 Million | 921.66 Million | 294.31 Million | 198.03 Million | 94.04 Million |
| Depreciation & Amortization | - | - | 332.37 Million | 92.68 Million | 78.4 Million | 77.07 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | - | - | -78.37 Million | - | - | - |
| Other non-cash items | -293.5 Million | -335.26 Million | 315.37 Million | -294.31 Million | -198.03 Million | -94.04 Million |
| Investing Cash Flow | - | - | -3.24 Billion | - | - | - |
| Investments in PPE | - | - | -648.14 Million | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | -2.59 Billion | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | -2.47 Billion | - | - | - |
| Financing Cash Flow | - | - | 1.83 Billion | - | - | - |
| Debt repayment | - | - | -2.08 Billion | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | 3.91 Billion | - | - | - |
| Other Financing Activities | - | - | 3.75 Billion | - | - | - |
| Accounts receivables | - | - | 196.46 Million | - | - | - |
| Accounts payables | - | - | 548.51 Million | - | - | - |
| Inventory | - | - | -354.88 Million | - | - | - |
| Other working capital | - | - | -468.47 Million | - | - | - |
| Cash at beginning of period | - | - | 266.11 Million | 503.63 Million | 346.81 Million | 266.11 Million |
| Cash at end of period | - | - | 2.66 Billion | 689 Million | 503.63 Million | 420.26 Million |
| Capital Expenditure | - | - | -648.14 Million | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | - | - | 2.39 Billion | 185.37 Million | 156.81 Million | 154.15 Million |
| Free Cash Flow | - | - | 568.24 Million | 185.37 Million | 156.81 Million | 154.15 Million |
SKHCF
CDGLY
MDTR
ZOREN
600703
8960